Erratum: The effective molecular characteristics of PD-1 inhibitor combination regimen as the first-line treatment for Chinese patients with HER2-positive gastric cancer: a real-world retrospective analysis study
Erratum to: Transl Gastroenterol Hepatol 2025;10:23
In the published article entitled “The effective molecular characteristics of PD-1 inhibitor combination regimen as the first-line treatment for Chinese patients with HER2-positive gastric cancer: a real-world retrospective analysis study” (Transl Gastroenterol Hepatol 2025;10:23. doi: 10.21037/tgh-24-95) (1), the superscript and affiliation of the corresponding author, Yan Wang, are incorrect and the order of Affiliated Unit 1 and Affiliated Unit 2 should be reversed. The updated superscript and affiliation for Yan Wang are provided below. The authors apologize for any inconvenience that it may have caused.
Lingyun Zhang1,2,3#, Bin Guan4,5#, Wei Li1,3, Shan Yu1,3, Qian Li1,3, Yiyi Yu1,3, Yuehong Cui1,3, Debin Sun6, Yan Wang1,3,7
1Department of Medical Oncology, Zhongshan Hospital, Fudan University, Shanghai, China; 2Department of Medical Oncology, Shanghai Geriatric Medical Center, Shanghai, China; 3Cancer Center, Zhongshan Hospital, Fudan University, Shanghai, China; 4Department of Research Center for Clinical Medicine, Jinshan Hospital, Fudan University, Shanghai, China; 5Department of Oncology, Shanghai Medical College, Fudan University, Shanghai, China; 6Department of Medicine, Genecast Biotechnology Co., Ltd, Wuxi, China; 7Shanghai Medical College and Zhongshan Hospital Immunotherapy Technology Transfer Center, Shanghai, China
#These authors contributed equally to this work.
Correspondence to: Yan Wang, MD, PhD. Department of Medical Oncology, Zhongshan Hospital, Fudan University, Fenglin Road 180, Shanghai 200032, China; Cancer Center, Zhongshan Hospital, Fudan University, Shanghai, China; Shanghai Medical College and Zhongshan Hospital Immunotherapy Technology Transfer Center, Shanghai, China. Email: wang.yan@zs-hospital.sh.cn.
The error has been corrected on the website.
Click here to view the updated version of the article.
Open Access Statement: This is an Open Access article distributed in accordance with the Creative Commons Attribution-NonCommercial-NoDerivs 4.0 International License (CC BY-NC-ND 4.0), which permits the non-commercial replication and distribution of the article with the strict proviso that no changes or edits are made and the original work is properly cited (including links to both the formal publication through the relevant DOI and the license). See: https://creativecommons.org/licenses/by-nc-nd/4.0/.
References
- Zhang L, Guan B, Li W, et al. The effective molecular characteristics of PD-1 inhibitor combination regimen as the first-line treatment for Chinese patients with HER2-positive gastric cancer: a real-world retrospective analysis study. Transl Gastroenterol Hepatol 2025;10:23. [Crossref] [PubMed]
Cite this article as: Editorial Office. Erratum: The effective molecular characteristics of PD-1 inhibitor combination regimen as the first-line treatment for Chinese patients with HER2-positive gastric cancer: a real-world retrospective analysis study. Transl Gastroenterol Hepatol 2025;10:76.
